Naiara Perurena

Group Leader

Instituto de Investigación Sanitaria Aragón
Country flagSpain

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (10)

Human epidermal growth factor receptor 2 positive (HER2+) tumors account for 20% of breast cancers. While a variety of HER2-targeted therapies have been developed, tumors can exhibit de novo or acquired resistance, and metastatic disease remains incurable. Here, we showed that EZH2 inhibitors shift the epigenetic state of HER2+ tumors, dramatically enhancing baseline responses to HER2 kinase inhibitors and re-sensitizing drug-resistant tumors in vitro and in vivo. Specifically, EZH2 silenced the pro-apoptotic gene BMF by catalyzing H3K27 trimethylation (H3K27me3) at regulatory sequences. EZH2 inhibitors promoted the loss of H3K27me3, but this stimulated the binding of repressive YAP/TEAD complexes at the BMF locus, which still restricted expression. However, in the presence of EZH2 inhibitors, HER2 kinase inhibitors triggered the dissociation of repressive YAP/TEAD complexes, potently upregulated BMF, and killed resistant cells. Accordingly, EZH2 inhibitors cooperated with genetic or pharmacological inhibition of YAP/TEAD, which similarly induced BMF expression and apoptosis. Together, these findings show how EZH2 and YAP/TEAD coordinately insulate the BMF locus and demonstrate that EZH2 inhibitors can be used to reprogram HER2+ tumors, resulting in a dramatic sensitization to HER2 kinase inhibitors and enhanced killing of residual disease.

Year:

2026

Year:

2024

Current treatments for KRAS-mutant colorectal cancers are often limited by cellular plasticity and rewiring responses. Here we describe a promising therapeutic strategy that simultaneously targets epigenetic and oncogenic signals. Specifically, we show that inhibitors of histone methyltransferase, EZH2, synergize with various rat sarcoma virus (RAS) pathway inhibitors and promote dramatic tumor regression in vivo. Together these agents cooperatively suppress Wingless and Int-1 (WNT)-driven transcription and drive colorectal cancers into a more differentiated cell state by inducing the Groucho/transducin-like enhancer corepressor, TLE4, along with a network of WNT pathway inhibitors and intestinal differentiation proteins. However, these agents also induce the proapoptotic protein BCL2 modifying factor (BMF), which subsequently kills these more differentiated cells. Accordingly, cell death can be prevented by activating β-catenin, by blocking differentiation, or by ablating BMF expression. Collectively, these studies reveal a new therapeutic approach for treating KRAS-mutant colorectal cancers and illustrate a critical convergence of EZH2 and RAS on oncogenic WNT signals, intestinal differentiation, and apoptosis. Significance: Combined EZH2 and RAS pathway inhibitors kill KRAS-mutant colorectal cancer cells and promote durable tumor regression in vivo. These agents function by cooperatively suppressing the WNT pathway, driving differentiation, and epigenetically reprogramming cells to permit the induction of apoptotic signals, which then kill these more differentiated tumor cells.

Year:

2024

Year:

2024

Year:

2024

Current treatments for KRAS -mutant colorectal cancers are often limited by cellular plasticity and rewiring responses. Here we describe a promising therapeutic strategy that simultaneously targets epigenetic and oncogenic signals. Specifically, we show that inhibitors of histone methyltransferase, EZH2, synergize with various rat sarcoma virus (RAS) pathway inhibitors and promote dramatic tumor regression in vivo . Together these agents cooperatively suppress Wingless and Int-1 (WNT)-driven transcription and drive colorectal cancers into a more differentiated cell state by inducing the Groucho/transducin-like enhancer corepressor, TLE4 , along with a network of WNT pathway inhibitors and intestinal differentiation proteins. However, these agents also induce the proapoptotic protein BCL2 modifying factor (BMF), which subsequently kills these more differentiated cells. Accordingly, cell death can be prevented by activating β-catenin, by blocking differentiation, or by ablating BMF expression. Collectively, these studies reveal a new therapeutic approach for treating KRAS- mutant colorectal cancers and illustrate a critical convergence of EZH2 and RAS on oncogenic WNT signals, intestinal differentiation, and apoptosis. Significance: Combined EZH2 and RAS pathway inhibitors kill KRAS- mutant colorectal cancer cells and promote durable tumor regression in vivo . These agents function by cooperatively suppressing the WNT pathway, driving differentiation, and epigenetically reprogramming cells to permit the induction of apoptotic signals, which then kill these more differentiated tumor cells.

Year:

2024

The DAB2IP tumor suppressor encodes a RAS GTPase-activating protein (RASGAP). Accordingly, DAB2IP has been shown to be mutated or suppressed in tumor types that typically lack RAS mutations. However, here we report that DAB2IP is mutated or selectively silenced in the vast majority of KRAS and BRAF mutant CRCs. In this setting, DAB2IP loss promoted tumor development by activating wild-type H- and NRAS proteins, which was surprisingly required to achieve robust activation of RAS effector pathways in KRAS-mutant tumors. DAB2IP loss also triggered production of inflammatory mediators and the recruitment of pro-tumorigenic macrophages in vivo. Importantly, tumor growth was suppressed by depleting macrophages or inhibiting cytokine/inflammatory mediator expression with a JAK/TBK1 inhibitor. In human tumors DAB2IP was lost at early stages of tumor development, and its depletion was associated with an enrichment of macrophage and inflammatory signatures. Together, these findings demonstrate that DAB2IP restrains the activation of the RAS pathway and inflammatory cascades in the colon and that its loss represents a common and unappreciated mechanism for amplifying these two critical oncogenic signals in colorectal cancer.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (8)

Sandro Santagata

Brigham and Women's Hospital

UNITED STATES
View details

Kimmie Ng

Associate Professor of Medicine, Harvard Medical School

Dana-Farber Cancer Institute

UNITED STATES
View details

Kristian Helin

CEO, Professor

Institute of Cancer Research

UNITED KINGDOM
View details

Karen Cichowski

Professor

Brigham and Women's Hospital

UNITED STATES
View details

Jennifer Morton

Professor

University of Glasgow

UNITED KINGDOM
View details

Owen J. Sansom

Director

Cancer Research UK Beatson Institute

UNITED KINGDOM
View details

Thuy Mai Van Nguyen

Imperial College London

UNITED KINGDOM
View details

PETER W LAIRD

Professor, Peter and Emajean Cook Endowed Chair in Epigenetics

Van Andel Institute

UNITED STATES
View details